Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

148.90GBp
7:42am EDT
Change (% chg)

-0.90p (-0.60%)
Prev Close
149.80p
Open
149.40p
Day's High
150.30p
Day's Low
146.10p
Volume
361,612
Avg. Vol
1,687,403
52-wk High
200.10p
52-wk Low
145.30p

VEC.L

Chart for VEC.L

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Overall

Beta: 0.45
Market Cap(Mil.): £1,012.16
Shares Outstanding(Mil.): 675.68
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): 131.06 36.91 37.71
EPS (TTM): 0.01 -- --
ROI: 1.98 15.22 14.43
ROE: 2.18 16.27 15.61

BRIEF-HBM Healthcare Investments: merger of Skyepharma and Vectura effective

* Recommended all share merger of Skyepharma and Vectura becomes effective

Jun 10 2016

BRIEF-Vectura FY core earnings rise 43 pct

* EBITDA(1) up 43% to £23.2m (2014/15: £16.2m) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

May 26 2016

BRIEF-Vectura & Propeller Health announce collaboration

* Vectura and propeller health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases Source text for Eikon: Further company coverage:

May 24 2016

BRIEF-Vectura Group says CMA not to investigate Vectura-Skyepharma merger

* CMA has confirmed that proposed recommended all share merger of Vectura and Skyepharma does not qualify for investigation

May 16 2016

BRIEF-UK's CMA says no relevant merger situation in Vectura-Skyepharma deal

* UK's CMA says decided that a relevant merger situation has not been created in anticipated acquisition by Vectura Group Plc of Skyepharma Plc Source text for Eikon:

May 16 2016

Drugmaker Vectura Group to buy SkyePharma

March 16 Drugmaker Vectura Group said on Wednesday it would buy SkyePharma Plc in an all-stock deal that would give it SkyePharma's drug delivery platform.

Mar 16 2016

BRIEF-HBM Healthcare Investments says Skyepharma to merge with Vectura group

* Under the terms of the proposed merger, Skyepharma shareholders will be entitled to receive 2.7977 new Vectura shares for every Skyepharma share

Mar 16 2016

BRIEF-Vectura Group to buy Skyepharma for 441.3 million stg

* Vectura Group and Skyepharma Plc have reached agreement on terms of a recommended merger between Vectura and Skyepharma

Mar 16 2016

BRIEF-Vectura says clinical study report for asthma therapy VR315 now final

* Next planned milestone and announcement scheduled for this programme is $10 million due to be paid upon acceptance for filing of ANDA by FDA

Feb 10 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Peel Hunt
$23.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.